Article
RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives - Blood Cancer Journal
Rating:
0.0
Views:
32
Likes:
1
Library:
1
NRAS and KRAS activating point mutations are present in 10–30% of myeloid malignancies and are often associated with a proliferative phenotype. RAS mutations harbor allele-specific structural and biochemical properties depending on the hotspot mutation, contributing to variable biological consequences.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value